Outpatient Prescriptions for Atypical Antipsychotics for African Americans, Hispanics, and Whites in the United States
- 1 February 2003
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of General Psychiatry
- Vol. 60 (2) , 121-8
- https://doi.org/10.1001/archpsyc.60.2.121
Abstract
New antipsychotic medications introduced during the past decade-clozapine (1990), risperidone (1994), olanzapine (1996), and quetiapine fumarate (1997)-offer a decrease in serious adverse effects compared with traditional antipsychotic medications, but at up to 10 times the cost. We examined whether ethnic minorities achieve access to these new advanced treatments. Using national data on physician office and hospital outpatient department visits from the National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey from 1992 through 2000, we selected all patient visits at which an antipsychotic medication (atypical or traditional) was prescribed or continued and the patient was aged between 18 and 69 years. We performed a series of cross-sectional logistic regression analyses to determine the association of ethnic group and receipt of an atypical antipsychotic prescription over time, adjusted for potential confounders such as age, diagnosis, and health insurance type. Antipsychotic medication was prescribed or continued in 5032 visits; 33% of overall visits involved an atypical antipsychotic prescription. During 1992 to 1994, the adjusted relative odds of receipt of an atypical antipsychotic prescription for African Americans was 0.50 (95% confidence interval [CI], 0.26-0.96) and for Hispanics was 0.43 (95% CI, 0.16-1.18) compared with whites. During 1995 to 1997, the odds of receipt of a prescription for atypical antipsychotics increased for African Americans (odds ratio [OR], 0.69; 95% CI, 0.54-0.85) and for Hispanics (OR, 0.84; 95% CI, 0.65-1.07) compared with whites; and during 1998 to 2000, the relative odds continued to increase for African Americans (OR, 0.88; 95% CI, 0.78-0.97) and for Hispanics (OR, 1.05; 95% CI, 0.92-1.16) compared with whites. For visits specified for psychotic disorders, receipt of atypical antipsychotics was still lower for African Americans by 1998 to 2000 (adjusted OR, 0.74; 95% CI, 0.61-0.89) compared with whites, while for Hispanics the relative odds was equivalent (adjusted OR, 1.05; 95% CI, 0.87-1.19). Early gaps between ethnic groups in receipt of atypical antipsychotic prescriptions decreased throughout the 1990s but persisted for African Americans with psychotic disorders.Keywords
This publication has 38 references indexed in Scilit:
- Association of Diabetes Mellitus With Use of Atypical Neuroleptics in the Treatment of SchizophreniaAmerican Journal of Psychiatry, 2002
- Clozapine Use in Patients With Schizophrenia and the Risk of Diabetes, Hyperlipidemia, and HypertensionArchives of General Psychiatry, 2001
- The Quality of Care for Depressive and Anxiety Disorders in the United StatesArchives of General Psychiatry, 2001
- Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysisBMJ, 2000
- Trends in the rate of depressive illness and use of antidepressant pharmacotherapy by ethnicity/race: an assessment of office-based visits in the United States, 1992–1997Clinical Therapeutics, 2000
- Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of lifeSchizophrenia Research, 2000
- Quality of Life and New Antipsychotics in Schizophrenia Are Patients Better Off?International Journal of Social Psychiatry, 1999
- Antipsychotic-Induced Weight Gain: A Comprehensive Research SynthesisAmerican Journal of Psychiatry, 1999
- Antipsychotics: Past and Future National Institute of Mental Health Division of Services and Intervention Research Workshop, July 14, 1998Schizophrenia Bulletin, 1999
- Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trialsSchizophrenia Research, 1998